These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27765799)

  • 101. Risk Factors and Preventions of Breast Cancer.
    Sun YS; Zhao Z; Yang ZN; Xu F; Lu HJ; Zhu ZY; Shi W; Jiang J; Yao PP; Zhu HP
    Int J Biol Sci; 2017; 13(11):1387-1397. PubMed ID: 29209143
    [TBL] [Abstract][Full Text] [Related]  

  • 102. High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia.
    Fu L; Fu H; Qiao J; Pang Y; Xu K; Zhou L; Wu Q; Li Z; Ke X; Xu K; Shi J
    Cancer Sci; 2017 Sep; 108(9):1850-1857. PubMed ID: 28670859
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
    Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
    J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Discovery of cancer common and specific driver gene sets.
    Zhang J; Zhang S
    Nucleic Acids Res; 2017 Jun; 45(10):e86. PubMed ID: 28168295
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
    Cordo Russo RI; Béguelin W; Díaz Flaqué MC; Proietti CJ; Venturutti L; Galigniana N; Tkach M; Guzmán P; Roa JC; O'Brien NA; Charreau EH; Schillaci R; Elizalde PV
    Oncogene; 2015 Jun; 34(26):3413-28. PubMed ID: 25174405
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.
    Venturutti L; Romero LV; Urtreger AJ; Chervo MF; Cordo Russo RI; Mercogliano MF; Inurrigarro G; Pereyra MG; Proietti CJ; Izzo F; Díaz Flaqué MC; Sundblad V; Roa JC; Guzmán P; Bal de Kier Joffé ED; Charreau EH; Schillaci R; Elizalde PV
    Oncogene; 2016 Apr; 35(17):2208-22. PubMed ID: 26212010
    [TBL] [Abstract][Full Text] [Related]  

  • 107. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.
    Elizalde PV; Cordo Russo RI; Chervo MF; Schillaci R
    Endocr Relat Cancer; 2016 Dec; 23(12):T243-T257. PubMed ID: 27765799
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
    Cordo Russo RI; Chervo MF; Madera S; Charreau EH; Elizalde PV
    Horm Cancer; 2019 Jun; 10(2-3):64-70. PubMed ID: 30656558
    [TBL] [Abstract][Full Text] [Related]  

  • 109. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
    Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
    Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 111. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.